312% Win in 24 Hours

Get our next setup.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

August 12, 2026 Morning,  I woke up this morning not feeling right about expiring access to Weekly Options Power Series so quickly.  And after reading some of the emails I received last night asking to keep it open for a little bit more time, I decided to extend it through tomorrow evening.  After that, it’ll close back up.  This isn’t just a random service we offer. It’s a package that’s actually delivering and has been all year…  By combining four trading services into one package, you’re accessing flexibility.  What do I mean by that?  Well, most trades are straight call or put buys, designed to capture sharp moves with the potential for triple-digit gains — without requiring a long-term commitment to the underlying stock.  And with markets reacting quickly to Fed expectations, economic data, earnings, and geopolitical headlines, volatility can spike fast. That’s where we deploy straddles — buying both a call and a put when we expect a major move but don’t want to bet on which direction it takes.  In other words, we’re not just betting on the market going up or down. We’re positioning for the size and speed of the move — exactly the kind of environment options can be built to capitalize on.  As a member of this package, you’ll receive around 17 trade recommendations per month. Each targeting up to 200% gains.  Just as we did with Alcoa early in July.  Entry: 6/29  Exit: 7/1  Gain: 430%  Or an even quicker win on Coherent LAST WEEK:  Entry: 8/3  Exit: 8/4  Gain: 312%  Yes, in just 24 hours.  I’m giving you the chance to see these firsthand – for only $15 compared to the standard $475.  Don’t miss this extension.  Join Weekly Options Power Series  Sincerely, Bernie Schaeffer Founder & CEO Schaeffer’s Investment Research 📧 service@sir-inc.com 📞 1-800-448-2080 🌍 1-513-589-3800 International   Update your email preferences or unsubscribe here © 2026 Schaeffer's Investment Research 5151 Pfeiffer Road, Suite 450 Cincinnati, Ohio 45242, United States

(Nasdaq: ENLV) Is On Our Radar This Morning — Under 90 Minutes to the Bell and Here Is What You Need to Know Right Now

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Krypton Street Just Put Enlivex (Nasdaq: ENLV) On The Radar This Morning—Wednesday, August 12, 2026 Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Here's Why ENLV Is In Focus This Morning… August 12, 2026 Dear Reader, Good morning. The bell rings in under 90 minutes. Last night, the full picture on Enlivex Ltd. (Nasdaq: ENLV) went out — the FDA RMAT designation for Allocetra, the $400M institutional commitment at $5 and $6 per share, the Rain protocol's $860M in July platform activity — up 622% over June — and a RAIN token treasury valued near $1.1Bn as of July 18, 2026. This morning, ENLV is still the first name on the screen. Here is what matters right now before the open. Fewer than 4M shares are listed as available to the public. According to Benzinga, H.C. Wainwright's Raghuram Selvaraju raised his published Bullish target to $80 last week — against a name that has been near the $2 range. That gap does not shrink overnight. The 182-patient Phase IIb trial is active across three countries. The FDA has requested a Type B meeting following the RMAT designation. And a single institution has $400M committed — with an option to put in another $400M over the next 36 months. The bell rings in under 90 minutes. Pull up ENLV before it does. But keep in mind, ENLV has less than 4M shares listed as available to the public right now. When companies have small floats like this, the potential exists for big moves if demand begins to shift. ENLV is currently trending around $2, but according to Benzinga, H.C. Wainwright analyst Raghuram Selvaraju raised his target to $80 last week, highlighting a substantial gap between current levels and his outlook. And there is another part of the ENLV story worth looking at: the company’s balance sheet and reported financial results. Enlivex reported FY2025 net income of $1.23B and diluted EPS of $25.48 — driven largely by appreciation in its RAIN token holdings. Total treasury and derivative assets stood at $2.31B, while shareholders’ equity reached $1.93B. About Enlivex Ltd. (Nasdaq: ENLV) Enlivex runs two strategies in parallel. The first is a clinical-stage immunotherapy program centered on Allocetra — an off-the-shelf, allogeneic cell therapy that reprograms macrophages back to their homeostatic state to resolve chronic inflammation. The lead indication is age-related primary knee osteoarthritis. The second is a digital asset treasury built around the RAIN protocol on Arbitrum. The active Phase IIb trial targets 182 patients aged 64 and older across the United States, Denmark, and Poland, with top-line data expected in 2027. Following the RMAT grant, the FDA requested a Type B meeting to align on Phase IIb design and late-stage development plans — an early, structured regulatory dialogue that is rare and valuable at this stage of development. By July 18, 2026, Enlivex held approximately 79.55Bn RAIN tokens valued at roughly $1.1Bn, with a reported unaudited mark-to-market NAV per share of $66.16. The company also carries an option on 271.37Bn additional tokens at $0.0033 per token — intrinsic value estimated near $2.23Bn as of May 2026. The Backdrop That Makes ENLV Worth a Closer Look The RMAT designation fundamentally changes the regulatory calculus for Allocetra. RMAT is not a routine milestone. The FDA grants it only when preliminary clinical evidence suggests a regenerative therapy can address a serious unmet need — and fewer than half of all RMAT applications are approved. That bar is high — and Allocetra cleared it based on Phase IIa data showing statistically significant, durable improvements in pain and function in the 60-plus cohort at three and six months. Osteoarthritis is projected to affect approximately 78M Americans by 2040, according to the CDC. The global osteoarthritis therapeutics market currently sits at $10.84Bn and is projected to reach approximately $26.31Bn by 2035 — a compound annual growth rate of 9.27%. That's the market backdrop. The 64-plus primary OA population — the specific group now targeted in Phase IIb — has no approved disease-modifying therapy within it. Every current pathway is symptomatic. Allocetra's mechanism targets macrophage polarization rather than broadly suppressing immunity, making it a structurally distinct candidate in a category where no approved therapy yet exists. The RAIN protocol side of the ledger is also moving. $860M in Rain protocol activity for July 2026 represents a 622% jump from June. With platform throughput targets of $1.3Bn (2027), $12Bn (2028), and $33Bn (2029), and a buyback-and-burn mechanism projected to generate $24M, $216M, and $600M in net fees at those levels, the structural demand driver for RAIN tokens — and for the treasury ENLV holds — becomes clearer. The NAV-to-market-cap gap remains wide. Readers who understand why it exists are better positioned to evaluate whether it narrows. What Has Happened at ENLV in the Last 90 Days FDA RMAT Designation for Allocetra (July 13, 2026) — The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra for the treatment of age-related symptomatic knee osteoarthritis in patients aged 64 and older. RMAT designation provides intensive, early FDA engagement and eligibility pathways for accelerated approval and priority review. Following the designation, the FDA requested a Type B meeting with Enlivex to conduct a comprehensive, multidisciplinary discussion of the Allocetra development program and Phase IIb planning. $400M Institutional Commitment (July 28, 2026) — A single institutional player agreed to purchase $400M of ENLV ordinary shares at $5 per share or $6 per share (RAIN tokens) — premiums of 17.4% and 40.8% to the July 27 close. The company holds an optional right to call an additional $400M from the same counterparty over 36 months. Closing requires shareholder approval. The buyer elected RAIN token funding, which election may be changed before close. RAIN Protocol Activity Reaches $860M (July 30, 2026) — The Rain protocol reported $860M in platform activity for July 2026, a 622% month-over-month increase versus June. Rain Foundation long-range throughput targets: $1.3Bn (2027), $12Bn (2028), $33Bn (2029), with projected buyback-and-burn proceeds of $24M, $216M, and $600M in those respective years. Treasury NAV Per Share of $66.16 (July 20, 2026) — As of July 18, 2026, Enlivex held approximately 79.55Bn RAIN tokens valued at roughly $1.1Bn. Unaudited mark-to-market NAV per ordinary share: $66.16. EULAR 2026 Oral Presentation (June 2026) — Phase IIa Allocetra data was selected for an oral podium presentation at the EULAR European Congress of Rheumatology in London, presented by Prof. Philip Conaghan. Results showed statistically significant and durable pain and function improvements in patients aged 60 and older at three and six months, with a favorable safety profile. Phase IIb First U.S. Patient Dosed (May 2026) — Enlivex dosed the first patient at a U.S. site in its Phase IIb Allocetra trial for age-related knee osteoarthritis. The 182-patient multicenter study spans the United States, Denmark, and Poland, targeting patients aged 64 and older following FDA IND and Danish Medicines Agency clearances. FY2025 Full-Year Results (March 25, 2026) — Net income of $1.23Bn. Diluted EPS of $25.48. Total treasury and derivative assets of $2.31Bn. Shareholders' equity of $1.93Bn. Cash and short-term digital assets of $30.0M as of December 31, 2025. 7 Reasons Why We Have ENLV At The Top Of Our Watchlist This Morning—Wednesday, August 12, 2026… 1. Low Float: With fewer than 4M shares listed as available to the public, ENLV’s small float could have the potential for big moves if demand begins to shift. 2. Analyst Target: With ENLV recently trending around $2, Benzinga reports that H.C. Wainwright analyst Raghuram Selvaraju raised his target to $80, creating a substantial gap between current levels and his published target. 3. FDA Designation: After Allocetra received RMAT designation for age-related knee osteoarthritis in patients 64 and older, ENLV gained access to more intensive FDA engagement and potential accelerated approval pathways. 4. Institutional Commitment: A single institution agreed to a $400M private placement at $5 to $6 per share, giving ENLV a significant proposed capital commitment that remains subject to shareholder approval and closing conditions. 5. RAIN Momentum: Following a reported 622% month-over-month increase to $860M in July platform activity, ENLV has growing exposure to the RAIN ecosystem through its substantial token treasury. 6. Treasury Value: As of July 18, Enlivex reported roughly $1.1B in RAIN holdings and an unaudited mark-to-market NAV of $66.16 per share, giving ENLV an unusual treasury component alongside its clinical program. 7. Clinical Progress: With a 182-patient Phase IIb study underway across the United States, Denmark, and Poland, ENLV has an active late-stage clinical catalyst with top-line data expected in 2027. Here's Why ENLV Is In Focus This Morning… There is a lot happening around ENLV at the same time, and that combination is what makes it worth keeping on your radar. The company has fewer than 4M shares listed as available to the public, an FDA RMAT designation for Allocetra, a proposed $400M private placement at $5 to $6 per share, and a 182-patient Phase IIb study underway across three countries. Then there is the RAIN side of the story. Enlivex reported roughly $1.1B in RAIN holdings as of July 18, along with an unaudited mark-to-market NAV of $66.16 per share, while Rain protocol platform activity climbed 622% month over month to $860M in July. And with ENLV recently hovering around $2, Benzinga reports that H.C. Wainwright analyst Raghuram Selvaraju raised his target to $80 — a substantial gap that gives readers another reason to study the story closely. None of these developments should be viewed in isolation. Together, they give ENLV several separate areas to watch: regulatory progress, clinical development, proposed financing, a relatively small public float, and a rapidly changing digital-asset treasury. We have all eyes on ENLV this morning. Take a look at ENLV while it’s still early. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 08/11/2026 and ending on 08/12/2026 to publicly disseminate information about (ENLV:US) via digital communications. Under this agreement, TD Media LLC has paid Media 1717 LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid twenty one thousand USD (“Funds”). These Funds were part of the thirty seven thousand five hundred USD funds that TD Media LLC received from a third party named Awareness Consulting Network LLC who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (ENLV:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/enlv-eEJgk/#details

Media 1717 LLC | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446 Unsubscribe About our service provider Sent by alex@kryptonstreet.com

Morning Watch: (NYSE: VNRX) Has Our Full Focus Right Now and the Bell Rings in Less Than 90 Minutes

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Market Crux Just Put VolitionRx Limited (NYSE: VNRX) On This Morning’s Watchlist—Wednesday, August 12, 2026 Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Pull Up VNRX While It’s Still Early… August 12, 2026 Dear Reader, Ninety minutes. That is the window between right now and the opening bell. If you read last night's report, you already know why VolitionRx Limited (NYSE: VNRX) has our full focus this morning. If you are seeing this for the first time, here is the short version. Q2 2026 earnings are due tomorrow, August 13. That is the first full quarter to capture everything that has happened at VNRX this summer — and this summer has been unusually active for a company with a market value near $9M. Six weeks ago, Sysmex Corporation signed a collaboration agreement with VNRX to optimize its Nu.Q® NETs H3.1 assay on the Sysmex platform. Sysmex operates in more than 190 countries and has been building diagnostics equipment since 1968. The agreement followed a verified technology transfer. Companies like Sysmex do not commit to an optimization phase unless the first phase held up. Then, on August 5, Volition announced the publication of the first peer-reviewed paper on its Capture-Seq™ liquid biopsy technology in Clinical Epigenetics. The method produces over 99% pure circulating tumor-derived DNA from a routine blood draw. The team detected 49 of 49 cancers in the first cohort and caught over 95% of Stage I and II cancers in a blinded validation. The combined TAM across multi-cancer early detection and Minimal Residual Disease sits at an estimated $36B. Active licensing discussions with several large diagnostic companies are already underway. Layer in Q1 revenue of nearly $1M — a 300% increase year-over-year — and the float sitting under 7M public shares, and the market has not caught up to what is sitting on the table heading into tomorrow's earnings. According to TipRanks, Justin Walsh at Jones has a $24 target on VNRX. Michael Okunewitch at Maxim Group holds a $4 target with a bullish rating. The bell rings in 90 minutes. Get VNRX on your screen before it does. We will have all eyes on VNRX at the open this morning. VNRX has fewer than 7M shares listed as available to the public. That is a small number. When floats get this tight, the potential exists for big swings once demand shifts. Now look at where it sits. VNRX is currently below $1 and drawing little attention. That combination has pushed the near-term momentum readings into rare territory. Barchart shows the Relative Strength Index on (VNRX) at 25.09 on a 9-day basis. 26.95 on 14-day. 29.17 on 20-day. Anything under 30 is what most technical readers call oversold. Some frameworks tie readings like these to the setup for a potential trend reversal. Several Analysts Have Taken Notice Maxim Group analyst Michael Okunewitch has a bullish rating on VNRX with a $4 target. And according to TipRanks, Justin Walsh at Jones raised his target on VNRX from $3 to $24, which suggests significant upside potential from its recent range. Revenue is moving too. Volition reported first-quarter 2026 revenue near $1Mn. That is a 300% increase over the same period last year. And Sysmex was not the only signed development to land here this summer. On July 7, 2026, Volition released real-world data on its Nu.Q Cancer assay. The work showed prognostic value in newly diagnosed lung cancer patients. It was produced alongside clinicians at Hospices Civils de Lyon. Clinical certification at that hospital system is already complete. A reimbursement submission in France is being prepared, with routine clinical use targeted before year end. That is the surface. Here is the foundation underneath it. What VNRX Actually Does VolitionRx Limited builds blood tests. That is the simple version. The longer one: it is a multi-national epigenetics company developing blood-based tests to detect and monitor cancer, plus diseases tied to NETosis, including sepsis. Research and development runs out of Belgium. There is an innovation lab and office in the United States, and an office in London. Headquarters sit in Henderson, Nevada. Roughly 67 people work there. Now here is the part that matters. Everything this company sells comes off one proprietary platform. It is called Nucleosomics. It measures nucleosomes and their epigenetic modifications as they circulate in your blood. From that single core, Volition built four separate commercial pillars. Four clinical problems. One research engine behind all of them. Pillar one is the furthest along. Nu.Q Vet already sells in more than 20 countries. The canine cancer test is live and generating revenue today. A feline version is next. It targets lymphoma, the most common cancer in cats. Volition submitted it for peer review after the assay detected 86% of feline lymphomas at 97% specificity. Publication is expected to unlock a $5Mn contractual milestone payment. Management also believes a feline test could roughly double what it can address in companion animal health. Pillar two is already in hospitals. Nu.Q NETs is CE-marked and clinically available across Europe. The market behind it runs an estimated $3.8Bn. Pillar three is close. Nu.Q Cancer is moving toward routine clinical use in lung cancer in France. Pillar four is the largest. Capture-Seq is the earliest-stage program, a liquid biopsy method the company estimates addresses roughly $23Bn a year. So where does the money come from today? Four places. Assay sales. Research services through Nu.Q Discover. Contractual milestone payments. And non-dilutive funding from Walloon Region agencies in Belgium. But licensing is where management expects the step change. Upfront payments. Milestones. Royalties from large diagnostics groups. And those conversations are already happening. The company has confirmed active discussions with more than a dozen of the world's leading diagnostics and liquid biopsy companies. Several are at the technical evaluation stage already. VNRX Is Aiming At A $36B Total Addressable Market Liquid biopsy is one of the few corners of diagnostics where clinical need and reimbursement are moving at the same time. The economics are simple. A blood draw that catches disease earlier costs a fraction of the imaging, biopsy, and late-stage treatment it replaces. So what has held the field back? Not the science. The cost. Sequencing-based approaches stay expensive enough that broad screening is hard to justify outside high-risk groups. Volition sits in that sector differently, in two ways. First, it is platform-based, not indication-based. Most companies this size build one test for one disease. One regulatory path. One point of failure. Volition's nucleosome chemistry covers cancer detection, sepsis triage, chronic inflammatory disease, and veterinary oncology off the same science. Several paths forward. One research budget. Second, it stays capital-light commercially. Now, the company estimates combined addressable markets above $36B across its pillars. The sepsis side deserves its own look. Published estimates put global sepsis cases near 166M a year. Sepsis-related deaths accounted for 31.5% of all global deaths in 2021. Volition's Nu.Q NETs assay is already inside DETECSEPS, a government-backed program in France worth roughly $7.3Mn. It starts in the third quarter of 2026. The VNRX Timeline Nobody Talked About — Until Now August 5, 2026 A World-First in Liquid Biopsy — Peer-Reviewed and Published Volition announced the publication of the first peer-reviewed paper on its Capture-Seq™ liquid biopsy technology in Clinical Epigenetics. The method produces over 99% pure circulating tumor-derived DNA from a routine blood draw. A blinded validation cohort showed over 95% sensitivity for Stage I and II cancers. The combined addressable market across multi-cancer early detection and Minimal Residual Disease is estimated at $36B. Active licensing discussions with several large diagnostic companies are already underway. July 7, 2026 Lung Cancer Data Lands With France's Second-Largest Hospital System Volition released clinical data showing the prognostic value of its Nu.Q® Cancer assay in newly diagnosed lung cancer patients, produced alongside researchers at Hospices Civils de Lyon. Clinical certification at HCL is already complete. A reimbursement submission targeting routine clinical use in France by Q4 2026 is being prepared. June 17, 2026 A Global Diagnostics Manufacturer Signs On Volition announced a collaboration with Sysmex Corporation (TYO: 6869) — a diagnostics manufacturer operating in more than 190 countries since 1968 — to optimize the Nu.Q® NETs H3.1 assay on the Sysmex platform. The agreement followed a successful technology transfer. Sysmex committed to an optimization phase because the first phase worked. June 3, 2026 New Patent Extends Nu.Q® NETs Into Ebola Triage Volition filed a strategic patent application covering use of its Nu.Q® NETs technology for triaging and monitoring patients suspected of contracting the Ebola virus — another demonstration of the platform's clinical reach beyond sepsis. The company stated it is seeking strategic partners to deploy the platform in affected regions. May 27, 2026 One Update, Four Pillars, $27B in Addressable Markets A consolidated corporate update detailed 300% first-quarter revenue growth, progress toward the $5M veterinary milestone, inclusion of Nu.Q® NETs as the sole biomarker in the $7.3M DETECSEPS sepsis program in France, and active licensing discussions with more than a dozen global diagnostics leaders. May 6, 2026 A $5M Payment Now Sits With Peer Reviewers Volition submitted for peer review a clinical manuscript on its Nu.Q® Vet Feline assay, which detected 86% of feline lymphomas at 97% specificity. Publication is expected to unlock a $5M contractual milestone payment from Antech/Heska. April 29, 2026 From Hospital Lab to Finger Prick Volition reported successful detection of nucleosomes in capillary blood from critically ill sepsis patients using a lateral flow prototype. The finger-prick format could extend Nu.Q® NETs testing to the bedside, the emergency room, and eventually point-of-care settings worldwide. 9 Reasons Why VNRX Is Topping Our Watchlist This Morning—Wednesday, August 12, 2026… 1. Earnings Ahead: with Q2 2026 results scheduled for Thursday morning, VNRX has a near-term corporate event arriving after an active stretch of company developments. 2. Tight Public Float: with fewer than 7M shares listed as publicly available, VNRX’s small float could witness the potential for big moves if demand begins to shift. 3. Sysmex Collaboration: following a successful technology transfer, VNRX entered an optimization-phase collaboration with Sysmex Corporation, whose analyzers are used across more than 190 countries. 4. Published Breakthrough: after its first Capture-Seq peer-reviewed paper appeared in Clinical Epigenetics, VNRX reported over 99% pure tumor-derived DNA and over 95% sensitivity for Stage I and II cancers in a blinded validation cohort. 5. Revenue Acceleration: after reporting Q1 2026 revenue near $1M and approximately 300% year-over-year growth, VNRX enters its upcoming quarterly report with measurable commercial progress already reported. 6. Licensing Discussions: with management confirming active discussions with more than a dozen leading diagnostics and liquid-biopsy companies, VNRX has multiple potential commercial relationships under technical evaluation. 7. Multiple Programs: spanning Nu.Q Vet, Nu.Q NETs, Nu.Q Cancer and Capture-Seq, VNRX has several programs advancing simultaneously across veterinary testing, sepsis, cancer detection and liquid biopsy. 8. Large Addressable Market: with management estimating combined addressable markets above $36B across its programs, VNRX is targeting several sizable diagnostic categories from one underlying platform. 9. Analyst Coverage with Maxim Group carrying a bullish rating and a $4 target while Jones reportedly raised its target from $3 to $24, VNRX has attracted notable coverage despite its roughly $9M market value. Pull Up VNRX While It’s Still Early… Market Crux looks for companies that have done more than the market has noticed. VNRX fits this mold. It has fewer than 7M shares available to the public. Its market value sits near $9M. It signed a collaboration agreement with one of the largest diagnostics manufacturers in the world. It published the first peer-reviewed paper on a liquid biopsy technology that isolates over 99% pure tumor-derived DNA from a routine blood draw — targeting a combined $36B addressable market. Revenue is running four times what it was a year ago. A $5M payment is waiting on a manuscript already sitting with peer reviewers. And Q2 2026 earnings land in 48 hours. The market has not put all of that together yet. That is why VNRX is topping our watchlist this morning. Take a look while it’s still early. Also, my next update could be on its way any moment, keep an eye out for it. Sincerely, Gary Silver Managing Editor, Market Crux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, MC is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 08/11/2026 and ending on 08/12/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, TD Media LLC has paid Headline Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid thirty thousand USD (“Funds”). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (VNRX:US). Please see important disclosure information here: https://marketcrux.com/disclosure/vnrx-IGrpN/#details

Headline Media | 7901 4th Street N, Suite 300, St. Petersburg, FL 33702 Unsubscribe About our service provider Sent by gary@marketcrux.net